Slc45a2 peptides for immunotherapy
OwnerGregory LIZÉE, Cassian YEE +2inventors
InventorsGregory LIZÉE, Cassian YEE, Patrick HWU, Janos ROSZIK
Life of this patent
Estimating the term…
Abstract
Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.
Claims30
An isolated peptide 35 amino acids in length or less and comprising the sequence of SLC45A2382-390 (SEQ ID NO:1) or SLC45A2393-402 (SEQ ID NO:2) or a sequence having at least 90% identity to SLC45A2382-390 (SEQ ID NO:1) or SLC45A2393-402 (SEQ ID NO:2), wherein the peptide selectively binds HLA-A2, HLA-A*0201, HLA-A24, or HLA-A*2402.
15-33. (canceled)
35-44. (canceled)
51-58. (canceled)
60-61. (canceled)
63-71. (canceled)
73-75. (canceled)
Dependencies are inferred from the claim text.